Altitude Acquisition (ALTU) has provided an announcement.
Altitude Acquisition Corp. has mutually terminated its business combination agreement with Picard Medical, Inc. without any termination fees and has instead entered a new agreement to merge with Vesicor Therapeutics, Inc., an early-stage biopharmaceutical company. Upon completion of the merger, subject to stockholder and regulatory approvals, Vesicor will become a wholly-owned subsidiary of Altitude, which will be renamed Vesicor Therapeutics, Inc. The merger’s finalization is contingent upon customary closing conditions, including the SEC’s approval of a Registration Statement. This strategic pivot aims to capitalize on Vesicor’s potential in microvesicle-based therapeutics.
For an in-depth examination of ALTU stock, go to TipRanks’ Stock Analysis page.
